Abstract #4056

進行結腸・直腸癌に対する1st-line化学療法としてのoxaliplatin + capecitabineとoxaliplatin + 5-FU：RCTのメタ解析

Capecitabine (CAP) versus 5-fluorouracil (FU) in combination with oxaliplatin (OX) as 1st-line chemotherapy (CT) for advanced colorectal cancer (ACRC): Meta-analysis of randomized clinical trials (RCT).

F. Cuppone, et al.

Abstract #4060

転移を有する大腸癌に対する血管新生阻害療法の効果: systematic reviewとmeta-analysisの初期的成績

Anti-angiogenic therapies for metastatic colorectal cancer (MCRC): Preliminary results of a systematic review and meta-analysis.

A. D. Wagner, et al.

Abstract #4064

転移を有する結腸・直腸癌を対象とした二次治療としてのFOLFIRIとFOLFIRI + panitumumabの第III相試験（20050181）：安全性に関するpooled dataの解析

Phase III study (20050181) of panitumumab with FOLFIRI vs FOLFIRI alone as 2nd-line treatment in patients with metastatic colorectal cancer (mCRC): Pooled safety data.

M. Peeters, et al.

Abstract #4092

局所進行直腸癌に対するUFT + LV連日同時投与を併用した術前照射療法：前向き・多施設共同第II相試験

Preoperative radiation with concurrent daily tegafur-uracil plus leucovorin for locally advanced rectal cancer. Results of a phase II multicenter prospective study.

P. Cellier, et al.

Abstract #4115

intergroup trial第III相試験（INT-0144試験、SWOG 9304試験）において5-FUと骨盤照射による直腸癌術後補助化学放射線療法を受けた患者の薬理遺伝学的解析のアップデート

An update of pharmacogenetic analysis of adjuvant rectal cancer patients treated with 5-fluorouracil and pelvic radiation in a phase III intergroup trial (INT-0144, SWOG 9304).

W. Zhang, et al.

Abstract #4116

FOLFOX療法を受けている症例におけるmethylentetrahydrofolate reductase(MTHFR)遺伝子の677C>Tおよび1298A>C遺伝子多型による治療効果予測

Predictive value of 677C>T and 1298C>A polymorphisms of the methylentetrahydrofolate reductase(MTHFR) gene in patients treated with FOLFOX therapy.

M. Etienne-Grimaldi, et al.

Abstract #4500

膵管癌のヌードマウス移植モデルの前向きな評価

A prospective validation of a direct tumor xenograft model in pancreatic ductal adenocarcinoma (PDA).

A. Jimeno, et al.

Abstract #4501

膵癌術前補助化学療法施行症例においてgemcitabineの代謝関連酵素の遺伝子多型と予後は相関する

Polymorphisms of genes involved in gemcitabine metabolism correlate with prognosis in patients receiving neoadjuvant therapy for pancreatic cancer.

M. M. Javle, et al.

Abstract #4502

進行膵癌に対するgemcitabine/bevacizumab/cetuximabとgemcitabine/bevacizumab・erlotinibの無作為化第II相試験の最終報告

Final analysis of a randomized phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC).

H. L. Kindler, et al.

Abstract #4503

膵腺癌における術後の予後予測を目的とした網羅的遺伝子発現検索

Use of whole genome expression analysis of pancreatic adenocarcinoma to predict prognosis after surgery.

E. A. Collisson, et al.

Abstract #LBA4504

CONKO-001試験：膵癌切除術後のgemcitabineを用いた補助化学療法と手術単独を比較した前向き多施設共同無作為化第III相試験の最終報告

CONKO-001:Final results of the randomaized, prospective, multicenter phase III trial of adjubant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC).

U. P. Neuｍann, et al.

Abstract #4505

Cisplatin + 5-FU + alpha-interferonを用いた膵癌術後補助化学放射線療法の多施設第II相試験：ACOSOG Z05031試験

ACOSOG Z05031: Report on a multicenter, phase II trial for adjuvant therapy of resected pancreatic cancer using cisplatin, 5-FU, and alpha-interferon.

V. J. Picozzi, et al.

Abstract #4509

アジア人における進行性肝細胞癌に対するsorafenib と placeboの無作為化
第III相試験

Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma.

A. Cheng, et al.

Abstract #4510

臨床stage II/IIIの胸部食道扁平上皮癌に対する5-FU + cisplatinによる術後補助化学療法と術前補助化学療法の無作為化比較試験：JCOG9907試験

A randomized trial of postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus neoadjuvant chemotherapy for clinical stage II/III squamous cell carcinoma of the thoracic esophagus (JCOG 9907).

H. Igaki, et al.

Abstract #LBA4511

漿膜浸潤を伴う進行胃癌に対する術後補助化学療法：mitomycin-C + 短期doxifluridine (Mf療法)に対するcisplatin腹腔内投与 + mitomycin-C + doxifluridine + cisplatin(iceMFP療法)の第III相試験：AMC0101(NCT00296322)

Postoperative adjuvant chemotherapy for grossly serosa-positive advanced gastric cancer: A randomized phase III trial of intraperitoneal cisplatin and early mitomycin-C plus long-term doxifluridine plus cisplatin (iceMFP) versus mitomycin-C plus short- term doxifluridine (Mf) (AMC 0101) (NCT00296322).

Y. Kang, et al.

Abstract #4512

局所進行または転移を有する胃癌に対する1st-line治療としてのdocetaxel + cisplatin (DC) vs 5-FU + LV + cisplatin (FLC) ：第III相試験のプレリミナリーな結果報告

Docetaxel-cisplatin (DC) versus 5-fluorouracyl-leucovorin-cisplatin (FLC) as first-line treatment for locally advanced or metastatic gastric cancer: preliminary results of a phase III study.

K. Ridwelski, et al.

Abstract #4537

切除不能な転移のある胃癌患者に対するS-1 + docetaxel + cisplatin併用療法の第II相試験

Phase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer.

Y. Sato, et al.

Abstract #4541

前治療のある進行再発胃癌に対するRAD001の多施設共同第II相試験

Multicenter phase II study of RAD001 for previously treated metastatic gastric cancer (MGC): Preliminary results.

K.Muro, et al.

Abstract #4543

胃癌における術後補助化学療法の重要性を評価する無作為化試験のメタ解析

Meta-analysis of randomized trials assessing the interest of postoperative adjubant chemotherapy in gastric cancer.

J. Sakamoto, et al.